U.S. Healthtech Stock News

Radian Group (RDN) has quietly rewarded patient shareholders, with the stock up about 10% over the past year and more than doubling over five years, even as annual revenue growth stays fairly flat. See our latest analysis for Radian Group. At a share price of $35.88, Radian’s steady climb, including a solid year to date share price return, lines up with its strong multi year total shareholder returns. This suggests momentum is still quietly building rather than fading. If Radian’s slow and...

The United States market has recently experienced declines in major stock indexes, with technology shares exerting downward pressure on the Nasdaq amid concerns about an AI bubble. In this environment, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and resilience against broader market volatility.

As the U.S. stock market grapples with volatility, driven by concerns over an AI bubble impacting technology stocks and recent interest rate decisions by the Federal Reserve, investors are keenly observing economic indicators for guidance. In such fluctuating conditions, identifying undervalued stocks becomes crucial as they can offer potential opportunities for growth when trading below their intrinsic value amidst broader market uncertainties.

As the United States stock market grapples with concerns over an AI bubble, technology shares have been under pressure, causing declines in major indices like the Nasdaq and Dow Jones Industrial Average. In such a volatile environment, companies with strong growth potential and high insider ownership can offer investors a sense of stability and alignment of interests between management and shareholders.

As the United States market experiences fluctuations, with technology shares weighing on major indices like the Nasdaq, investors are closely monitoring economic indicators and Federal Reserve actions. In this context, penny stocks—often seen as smaller or newer companies—remain a compelling area of interest due to their potential for growth when backed by strong financials. Despite being an outdated term, these stocks can offer unique opportunities for investors seeking to uncover hidden...

With a price-to-sales (or "P/S") ratio of 1.1x Celularity Inc. ( NASDAQ:CELU ) may be sending very bullish signals at...

As the United States market experiences fluctuations with technology shares impacting major indices like the Nasdaq and S&P 500, investors are keenly observing economic indicators such as employment data and retail sales for insights into small-cap performance. In this dynamic environment, identifying promising small-cap stocks can be crucial, as these companies often offer unique growth opportunities that may not yet be reflected in broader market trends.

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

MGE Energy, Inc. ( NASDAQ:MGEE ), might not be a large cap stock, but it saw significant share price movement during...

Healthcare Realty Trust (HR) is back in focus after Cantor Fitzgerald backed its ongoing strategic overhaul, highlighting that the REIT’s planned asset sales of more than 1 billion dollars align with falling cap rates in medical office deals. See our latest analysis for Healthcare Realty Trust. That backdrop helps explain why, even with the latest share price at $17.18 and a softer 1 month share price return, Healthcare Realty Trust still shows a positive year to date share price return and...

In early December 2025, UL Solutions Inc. completed a US$975 million follow-on equity offering of 12,500,000 Class A common shares at US$78 each, with UBS Securities LLC joining as co-lead underwriter. This sizeable equity raise expands UL Solutions’ financial flexibility, potentially influencing how investors think about its funding mix, growth investments, and future dilution. With this large equity raise now completed, we’ll explore how it may reshape UL Solutions’ investment narrative...

Aon (AON) has escalated its rivalry with Howden into the courts, alleging a coordinated raid on its US brokerage talent and confidential data that pulled more than 45 employees toward the competitor. See our latest analysis for Aon. Despite the legal flare up with Howden and a steady drumbeat of operational updates, Aon’s latest share price of $353.79 leaves it roughly flat year to date on a share price return basis. At the same time, a solid five year total shareholder return of about 76...

ONEOK (OKE) has been drifting after a choppy stretch for energy names, but the stock’s recent pullback contrasts with its solid profit growth and invites a closer look at whether the market is over-discounting execution risk. See our latest analysis for ONEOK. Over the past year, ONEOK’s share price return has been pressured by shifting sentiment toward energy demand and rate expectations, even as its 5 year total shareholder return of 150.03% points to a business that has historically...

In December 2025, Elanco Animal Health used its Investor Day to outline cost-saving reorganizations, fresh U.S. R&D and manufacturing investments, and meaningful regulatory progress toward USDA approval for its Befrena™ canine dermatitis therapy. Taken together, the planned Elanco Ascend productivity gains, expanded innovation footprint, and a potential first-in-class pet immuno-therapeutic highlight a sharpened focus on higher-value growth opportunities. Now we'll examine how Elanco's...

Modine Manufacturing (MOD) is back on investors radar after fresh Buy ratings from D.A. Davidson and UBS, both pointing to the company’s growing role in data center cooling and its potential for long term revenue expansion. See our latest analysis for Modine Manufacturing. The latest pullback, including a 1 day share price return of minus 15.3 percent, comes after a strong run. Year to date share price gains are still above 20 percent and a remarkable multi year total shareholder return above...

Vestis (VSTS) just posted fourth quarter and full year 2025 results that deepened its losses even as revenue held roughly steady, and management guided 2026 sales to be flat to slightly lower, spotlighting ongoing execution challenges. See our latest analysis for Vestis. Despite that cautious outlook, investors have been speculating on a turnaround, with a 30 day share price return of 42.32 percent and a 90 day share price return of 84.91 percent, even though the 1 year total shareholder...

In December 2025, Teradyne Robotics announced plans to open a new U.S. Operations Hub in Wixom, Metro Detroit, from 2026, focused on manufacturing Universal Robots cobots, expanding training and service capabilities, and creating over 200 jobs to support advanced manufacturing across the Americas. The choice of Michigan’s manufacturing corridor and the potential to add MiR autonomous mobile robots highlight Teradyne’s push to be physically closer to key industrial customers while aligning...

Loews Corporation recently announced that long-serving directors Ann E. Berman and Charles M. Diker will retire from its Board at the 2026 Annual Meeting, with the Board expected to shrink to ten members, and received a largely favorable Delaware Supreme Court ruling related to its 2018 Boardwalk Pipelines transaction. These board changes, combined with continued revenue and earnings growth driven by CNA Financial’s improved underwriting and higher investment income, highlight how Loews is...

Guardant Health (GH) just deepened its footprint in oncology research with a new alliance, pairing its liquid biopsy data with Trial Library’s AI platform to make cancer trial access smoother and more equitable across the United States. See our latest analysis for Guardant Health. Those kinds of partnerships have landed at a moment when sentiment has already turned sharply, with Guardant’s 90 day share price return of 84.24 percent and year to date share price gain of 221.28 percent signaling...

In early December 2025, The Campbell's Company reported first‑quarter fiscal 2026 results showing net sales of US$2,677 million and net income of US$194 million, both down from a year earlier, while also issuing US$548.812 million of 4.550% senior unsecured notes due 2031 priced slightly below par. The combination of softer volumes, pressure on margins, high short interest, and fresh debt issuance has sharpened investor focus on Campbell’s balance sheet strength and its ability to improve...

In the past week, Monolithic Power Systems, Inc. declared a fourth-quarter cash dividend of US$1.56 per share, payable on January 15, 2026, to shareholders of record as of December 31, 2025. The dividend announcement comes alongside the company’s upcoming inclusion in the Nasdaq 100 Index, underlining its growing scale and profile in global power semiconductor markets. We’ll now explore how the Nasdaq 100 inclusion may influence Monolithic Power Systems’ existing investment narrative around...

Earlier this month, Sotera Health reported stronger-than-expected third-quarter 2025 results and affiliates of Warburg Pincus and GTCR launched a 30 million-share secondary offering, for which Sotera will cover expenses but receive no proceeds. On the same day, Chairman and CEO Michael B. Petras Jr. sold 749,199 Sotera shares for about US$12.3 million, spotlighting insider activity just after the earnings beat. Now, we'll explore how the CEO's sizeable share sale and the secondary offering...

AppFolio (APPF) just caught fresh attention after UBS kicked off coverage with a Buy call. The firm highlighted steady customer spending and limited competitive pressure, a backdrop that helps frame the stock’s recent pullback. See our latest analysis for AppFolio. That upbeat call lands after a choppy stretch, with the share price at $231.43 posting a 30 day share price return of negative 6.67 percent and a 1 year total shareholder return of negative 12.22 percent, even as the three year...

Recently, Raymond James initiated coverage on Phathom Pharmaceuticals with a Strong Buy rating as the company posted third-quarter 2025 results that exceeded forecasts, raised its full-year revenue guidance, and advanced Voquezna as the first and only FDA-approved PCAB for GERD. Phathom also started a Phase 2 trial of VOQUEZNA tablets in eosinophilic esophagitis, underscoring how a single asset is being expanded across multiple gastrointestinal indications. Next, we’ll examine how the...